Afatinib/erlotinib/gefitinibAcquired resistance in non-small cell lung cancer: case report

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-018-47032-5
中图分类号
学科分类号
摘要
引用
收藏
页码:15 / 15
相关论文
共 50 条
  • [31] Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report
    REN ShengxiangZHOU SongwenZHANG Ling and ZHOU Caicun Department of Medical OncologyTongji University Affiliated Shanghai Pulmonary Hospital
    Tongji University Medical School Cancer InstituteShanghai China
    中华医学杂志(英文版), 2010, (23) : 3501 - 3503
  • [32] Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report
    Ren Sheng-xiang
    Zhou Song-wen
    Zhang Ling
    Zhou Cai-cun
    CHINESE MEDICAL JOURNAL, 2010, 123 (23) : 3501 - 3503
  • [33] Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
    Karachaliou, Niki
    Codony-Servat, Jordi
    Paulina Bracht, Jillian Wilhelmina
    Ito, Masaoki
    Filipska, Martyna
    Pedraz, Carlos
    Chaib, Imane
    Bertran-Alamillo, Jordi
    Felipe Cardona, Andres
    Angel Molina, Miguel
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (10) : 1019 - 1028
  • [34] Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
    Pal, A. S.
    Bains, M.
    Agredo, A.
    Kasinski, A. L.
    BIOCHEMICAL PHARMACOLOGY, 2021, 189
  • [35] Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
    Ramos, German. E. E.
    Caglevic, Christian
    Bulnes, Juan. F. F.
    Panay, Sergio. E. E.
    Zapata, Mario. I. I.
    Daniele, Andres J.
    Rodriguez, Manuel. E. E.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [36] Erlotinib in non-small cell lung cancer: a review
    Blackhall, FH
    Rehman, S
    Thatcher, N
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 995 - 1002
  • [37] Erlotinib in the treatment of non-small cell lung cancer
    Brown, Ewan R.
    Shepherd, Frances A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 767 - 775